Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Gilson

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
The Lancet. HIV|June 4, 2021
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIVEmma Touizer, Aljawharah Alrubayyi, Chloe Rees-Spear, et al.
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi, Jo Turner, Richard Gilson, et al.
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
Women'S Health (London, England)|January 13, 2022
Association between health-related quality of life and menopausal status and symptoms in women living with HIV aged 45-60 years in England: An analysis of the PRIME studyHajra Okhai, Livia Dragomir, Erica Rm Pool, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Lancet (London, England)|July 13, 2020
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workersCatherine F Houlihan, Nina Vora, Thomas Byrne, et al.
AIDS (London, England)|September 12, 2008
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study, Katherine J Lee, David Dunn, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
The Lancet. HIV|June 4, 2021
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIVEmma Touizer, Aljawharah Alrubayyi, Chloe Rees-Spear, et al.
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi, Jo Turner, Richard Gilson, et al.
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
Women'S Health (London, England)|January 13, 2022
Association between health-related quality of life and menopausal status and symptoms in women living with HIV aged 45-60 years in England: An analysis of the PRIME studyHajra Okhai, Livia Dragomir, Erica Rm Pool, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Lancet (London, England)|July 13, 2020
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workersCatherine F Houlihan, Nina Vora, Thomas Byrne, et al.
AIDS (London, England)|September 12, 2008
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study, Katherine J Lee, David Dunn, et al.
Pageof 15